SHTG Daily Digest — Weiss Lab

A quiet cycle overall — no top-tier journal papers on our core targets cleared the bar and no genuinely new industry news broke in the last five days, so this episode leans on two next-best-tier papers (an ANGPTL3-inhibitor phase 3 extension and a pediatric SHTG risk-prediction study) while the Arrowhead/Ionis/Alnylam news front stayed silent beyond what's already been covered.

A quiet science week surfaces a novel APOC3 role in diabetic retinal angiogenesis and a diagnostic yield study for monogenic HTG, while the industry story remains Ionis' Tryngolza commercial launch into the 3.6-million-patient sHTG market following last week's FDA approval.

The week's dominant story is the FDA's June 24 approval of Ionis' Tryngolza (olezarsen) as the first-ever treatment for severe hypertriglyceridemia with a pancreatitis risk reduction claim; on the science side, three next-best-tier papers examine plozasiran's pharmacology, ApoC3's biphasic role across the MASLD spectrum, and urinary ANGPTL3 as a novel biomarker for podocyte injury.

A fresh meta-analysis of 14 APOC3-inhibitor trials confirms 80% reduction in acute pancreatitis risk alongside a compelling indirect head-to-head of olezarsen versus volanesorsen in FCS, while the most important industry event this cycle is the looming June 30 FDA decision on Tryngolza for severe hypertriglyceridemia.

A quiet breaking-news cycle on paper, but the lipid field is coiled for impact — a landmark Ionis FDA decision on olezarsen for severe hypertriglyceridemia is 11 days out, and fresh science clarifies who among heterozygous FCS-gene carriers will need APOC3-targeted therapy; on the bench, a novel SPP2–LPL axis offers a new handle on triglyceride homeostasis.

A meta-analysis confirms olezarsen's strong efficacy across eight RCTs, a human kinetic study illuminates exactly how ANGPTL3 deficiency reshapes triglyceride-rich lipoprotein metabolism, and a JACC case report highlights the management challenges of severe HTG in pregnancy — while the industry stage is quiet mid-week but poised for major events: the FDA PDUFA date for Tryngolza in sHTG arrives June 30, and Arrowhead's SHASTA-3/4 phase 3 readout is expected this month.

A quiet cycle on both fronts — no new top-tier lipid papers cleared the bar (the one journal hit, a Lancet D&E retrospective, was already covered Tuesday), and no fresh trade-press stories landed in the 5-day window, leaving the competitive backdrop dominated by the countdown to the FDA's June 30 decision on olezarsen in severe hypertriglyceridemia.

A sweeping 25-year review of lipid medicine published today in *Lancet Diabetes & Endocrinology* maps the journey from statins to RNA/DNA-targeted therapies for APOC3 and ANGPTL3; on the industry side, it's a quiet news week, but the Ionis FDA clock for Tryngolza in severe hypertriglyceridemia is now ticking down to a June 30 decision.

Circulation Research publishes a landmark trio of review articles on triglyceride-rich lipoprotein biology and RNA-targeted therapies today, while on the industry side it is a quiet week — but the Ionis Tryngolza FDA decision in sHTG is now just 25 days away and Arrowhead's SHASTA-3/4 phase 3 readouts are imminent.

A PNAS study reveals GPIHBP1 on brain oligodendrocytes as a novel docking site for LPL in the CNS, while an updated meta-analysis consolidates olezarsen's case as a potent APOC3-targeting therapy; on the industry side, a quiet week ahead of Ionis' looming June 30 FDA decision for Tryngolza in sHTG.

A quiet week on top-tier journal lipid papers, but four solid next-tier publications span plozasiran's approval story, a machine-learning breakthrough for predicting which HTG patients will develop pancreatitis, lipidomic signatures of drug-refractory HTG, and pediatric monogenic HTG genetics; on the industry side, Ionis's platform scores a landmark hepatitis B win this week, keeping the ASO powerhouse in the spotlight while its Tryngolza sHTG approval decision looms by June 30.

A landmark Circulation imaging trial finds that olezarsen's dramatic triglyceride lowering does not translate into coronary plaque regression at 12 months—raising fundamental questions about TG-lowering as an atherosclerosis therapy just as the 2026 ACC/AHA dyslipidemia guideline reframes how we should think about hypertriglyceridemia, and with Ionis's PDUFA date for the SHTG indication just five weeks away.

A landmark ACC/AHA dyslipidemia guideline dropped this week alongside a pivotal Circulation imaging trial showing olezarsen's dramatic triglyceride reduction does not translate into coronary plaque regression — a sobering finding that reframes what APOC3 inhibition can and cannot achieve at 12 months; on the industry side, the two biggest near-term catalysts remain Ionis' June 30 PDUFA date for olezarsen in sHTG and Arrowhead's expected EU approval of REDEMPLO, both just outside this cycle's lookback window but essential context.

A landmark Circulation imaging trial shows olezarsen dramatically lowers triglycerides but does not shrink coronary plaque, while two new meta-analyses confirm robust TG and pancreatitis benefits across the ApoC-III inhibitor class, and on the industry side both Arrowhead and Ionis are sprinting toward a mid-2026 collision in the sHTG market.

A quiet top-tier journal week — no NEJM/Lancet/JAMA hits, but the next tier delivered three substantial APOC3-inhibitor meta-analyses (olezarsen, plozasiran, and the full ApoC-III class) all landing the same message: large triglyceride drops and a dramatic ~80% cut in acute pancreatitis risk, plus a new HNF4A–SPP2–LPL axis that could expand the SHTG target list; the industry side was equally subdued, dominated by Madrigal's $1B-biobucks pickup of an Arrowhead RNAi MASH asset and the run-up to Ionis' Tryngolza sHTG PDUFA at the end of June.

A thin top-tier journal week pushed Part A to the next-best tier, where ApoC-III inhibitors keep stacking up favorable meta-analytic evidence and a new HNF4A–SPP2–LPL axis hints at fresh small-molecule entry points; the industry side is also quiet — the dominant story over the past seven days remains the run-up to the late-June Tryngolza sHTG PDUFA, with no major company-specific lipid news from the allowed outlets.

No top-tier journal acromegaly-style hits this cycle, but the broader lipid literature delivered two useful APOC3-inhibitor / olezarsen meta-analyses and a timely RNAi-for-lipid-disorders review; Part B was a quiet news week for Arrowhead, Alnylam, and Ionis specifically, with the Tryngolza severe-hypertriglyceridemia FDA decision (due by June 30) the dominant near-term catalyst.

No top-tier journal hits surfaced this week — showing the next-best tier — but the haul is unusually substantive: the first randomized evidence that an APOC3 siRNA (plozasiran) prevents recurrent pancreatitis in very severe hypertriglyceridemia, a major Hegele review repositioning ANGPTL3 as a remnant-cholesterol target, and new human data linking ANGPTL3/4/8 complexes to heart failure outcomes.

A genuinely consequential week — the 2026 ACC/AHA dyslipidemia guideline lands in Circulation and explicitly incorporates hypertriglyceridemia and Lp(a) management, while NEJM publishes a three-letter correspondence exchange that pressure-tests the CORE-TIMI 72 olezarsen pancreatitis data.

This week's top-tier literature is anchored by the new 2026 ACC/AHA Dyslipidemia Guideline — the most comprehensive update to U.S. lipid management in eight years — alongside a cluster of NEJM correspondence debating the landmark olezarsen APOC3-targeting RCT and its implications for pancreatitis prevention in severe hypertriglyceridemia.

A thin but consequential week — the new 2026 ACC/AHA multisociety dyslipidemia guideline lands in Circulation with hypertriglyceridemia and Lp(a) carved out as first-class targets, and three NEJM correspondence pieces continue the post-publication debate over olezarsen's pancreatitis benefit in severe hypertriglyceridemia.

A quiet week for new mechanistic and trial data, but two notable items: the 2026 ACC/AHA dyslipidemia guideline drops in Circulation (now formally folding hypertriglyceridemia into the same document as cholesterol), and three independent correspondence letters in NEJM probe the olezarsen pancreatitis-risk findings reported earlier this year by the TIMI group.

A thin original-research week, but two genuinely high-impact items: the new joint 2026 ACC/AHA dyslipidemia guideline (which now formally addresses hypertriglyceridemia and Lp(a) alongside LDL-C), and three published letters in NEJM debating the CORE-TIMI 72a/b olezarsen trial — including the Marston/Bergmark/Sabatine reply.

A thin but consequential week — the new 2026 ACC/AHA dyslipidemia guideline lands in *Circulation* and explicitly folds hypertriglyceridemia into the cholesterol-management framework, while *NEJM* publishes a correspondence cluster pressure-testing the pancreatitis-risk findings of the pivotal olezarsen (APOC3) trial.

A landmark week — the ACC/AHA released the first major U.S. dyslipidemia guideline since 2018, plozasiran's PALISADE post-hoc shows it prevents recurrent pancreatitis in very severe hypertriglyceridemia (and now has its first regulatory approval), and two new Nature Reviews Cardiology pieces frame the next phase for ApoC-III– and ANGPTL3-directed therapies.

The long-awaited 2026 ACC/AHA Dyslipidemia Guideline drops today in *Circulation*, while concurrent evidence on plozasiran, ANGPTL3 inhibition, and ApoC-III blockade reinforces that RNA-based triglyceride therapies are reshaping the clinical landscape for SHTG and residual cardiovascular risk.

The week's literature is dominated by meta-analytic syntheses of APOC3-targeting agents (olezarsen and plozasiran) and ANGPTL3 inhibitors, converging on a consistent message — both pathways produce profound TG lowering with acceptable safety profiles, and plozasiran in particular now has the first prospective RCT evidence for reducing recurrent acute pancreatitis in FCS patients.